Nifty Pharma slides 1.64% to 21,617.25, marking a five‑session decline amid US levy threats for generics.

• Top losers include Natco Pharma (3.42%), Laurus Labs (3.32%), Abbott India (2.63%), and Gland Pharma (2.56%).
• Generic manufacturers are exempt from levies, sustaining low‑cost export revenues to the United States market currently.
• White House urges onshoring; Trump warns levies could soar up to 200% without localized production.